Clene Inc (CLNNW) - Total Liabilities
Based on the latest financial reports, Clene Inc (CLNNW) has total liabilities worth $34.67 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Clene Inc - Total Liabilities Trend (2017–2024)
This chart illustrates how Clene Inc's total liabilities have evolved over time, based on quarterly financial data. See CLNNW net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Clene Inc Competitors by Total Liabilities
The table below lists competitors of Clene Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Kardan NV
TA:KRNV
|
Israel | ILA721.20 Million |
|
Ordinary Fully Paid Deferred Settlement
AU:1TTDB
|
Australia | AU$243.99K |
|
Hall of Fame Village LLC
NASDAQ:HOFVW
|
USA | $325.72 Million |
|
Jasmine International Public Company Limited
F:JASN
|
Germany | €7.08 Billion |
|
Lexaria Bioscience Corp
NASDAQ:LEXXW
|
USA | $1.53 Million |
|
Aquis Exchange PLC
LSE:AQX
|
UK | GBX7.47 Million |
|
BriaCell Therapeutics Corp
NASDAQ:BCTXW
|
USA | $3.35 Million |
Liability Composition Analysis (2017–2024)
This chart breaks down Clene Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Clene Inc worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.53 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.81 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.55 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Clene Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Clene Inc (2017–2024)
The table below shows the annual total liabilities of Clene Inc from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $36.19 Million | -7.08% |
| 2023-12-31 | $38.95 Million | -5.59% |
| 2022-12-31 | $41.26 Million | -18.25% |
| 2021-12-31 | $50.47 Million | -25.68% |
| 2020-12-31 | $67.90 Million | +579.70% |
| 2019-12-31 | $9.99 Million | -76.31% |
| 2018-12-31 | $42.16 Million | +43190.89% |
| 2017-12-31 | $97.39K | -- |
About Clene Inc
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis … Read more